Department of Endocrinology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Pathophysiology, Hebei Medical University, Shijiazhuang, Hebei, China.
Front Endocrinol (Lausanne). 2024 Nov 11;15:1421838. doi: 10.3389/fendo.2024.1421838. eCollection 2024.
Diabetic cardiomyopathy (DCM) is defined as structural and functional cardiac abnormalities in diabetes, and cardiomyocyte death is the terminal event of DCM. Ferroptosis is iron-dependent oxidative cell death. Evidence has indicated that iron overload and ferroptosis play important roles in the pathogenesis of DCM. Mitochondria, an important organelle in iron homeostasis and ROS production, play a crucial role in cardiomyocyte ferroptosis in diabetes. Studies have shown some anti-diabetic medicines, plant extracts, and ferroptosis inhibitors might improve DCM by alleviating ferroptosis. In this review, we systematically reviewed the evidence of ferroptosis in DCM. Anti-ferroptosis might be a promising therapeutic strategy for the treatment of DCM.
糖尿病心肌病（DCM）被定义为糖尿病中的结构性和功能性心脏异常，而心肌细胞死亡是 DCM 的终末事件。铁死亡是一种依赖于铁的氧化细胞死亡。有证据表明，铁过载和铁死亡在 DCM 的发病机制中起重要作用。线粒体是铁稳态和 ROS 产生的重要细胞器，在糖尿病中心肌细胞铁死亡中起关键作用。研究表明，一些抗糖尿病药物、植物提取物和铁死亡抑制剂可能通过减轻铁死亡来改善 DCM。在这篇综述中，我们系统地回顾了铁死亡在 DCM 中的证据。抗铁死亡可能是治疗 DCM 的一种很有前途的治疗策略。
